ArticleCytometry. Part B, Clinical cytometry2010
Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population.
Article in Cytometry. Part B, Clinical cytometry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Trial
- Inertial Microfluidics Enabling Clinical Research.Micromachines · 2021Review
- Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.American journal of physiology. Heart and circulatory physiology · 2019Review
- Vascular Health Profile predicts cardiovascular outcomes in patients with diabetes.Cytometry. Part B, Clinical cytometry · 2017Article
- Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.Circulation · 2015Article
- Microvesicles and diabetic complications--novel mediators, potential biomarkers and therapeutic targets.Acta pharmacologica Sinica · 2014Review
- Endothelial microparticles: sophisticated vesicles modulating vascular function.Vascular medicine (London, England) · 2013Review
- Arterial erectile dysfunction: reliability of new markers of endothelial dysfunction.Journal of endocrinological investigation · 2011Article
- Circulating endothelial progenitor cells and cellular membrane microparticles in db/db diabetic mouse: possible implications in cerebral ischemic damage.American journal of physiology. Endocrinology and metabolism · 2011Article
- Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.The review of diabetic studies : RDSReview
- Personalized cytomic assessment of vascular health: Evaluation of the vascular health profile in diabetes mellitus.Cytometry. Part B, Clinical cytometryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveQuantitative measures are needed to identify diabetic patients at higher risk for CV events. Cell-derived microparticles (MPs) are submicron membrane vesicles released from activated cells that are indicative of cell damage. Progenitor cells (PCs) including proangiogenic cells (PACs), often termed endothelial progenitor cells (EPCs), are mediators of reparative capacity. We examined whether the relationship of MPs to PCs/PACs could be used as an improved and clinically feasible index of vascular pathology. METHODS AND
resultsPlasma samples were collected from patients with early-stage (ES, Diagnosis < 1 year) and long-term (LT, Diagnosis > 5 years,) Type 2 diabetes and compared with age related healthy subjects (H). PC and MP subtypes were measured by a combination of flow cytometry and ELISA-based methods. The ratio of procoagulant MPs/CD34(+) PCs proved a valuable index to distinguish between subject groups (P = 0.01). This index of compromised vascular function was highest in the LT group despite intensive statin therapy and was more informative than a range of soluble protein biomarkers.
conclusionsThis is the first report of a relationship between MPs and PCs in Type 2 diabetes. This ratio may provide a quantitative and clinically feasible measurement of vascular dysfunction and cardiovascular risk in patients with diabetes. © 2010 International Clinical Cytometry Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.